New blood pressure combo pill aims to beat standard treatment

NCT ID NCT06643819

Recruiting now Disease control Sponsor: Chong Kun Dang Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a combination pill containing sacubitril and valsartan (CKD-202A) works better than valsartan alone for essential hypertension. About 324 adults with high blood pressure will take either the combo or the standard drug for 10 weeks. The main goal is to see if the combo lowers average systolic blood pressure more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril/valsartan (a combination drug that helps relax blood vessels and reduce fluid buildup)
What this could lead to: If successful, this could provide a more effective once-daily pill for controlling high blood pressure compared to current standard treatments.
What could go wrong: This is a confirmatory phase 3 trial, but the drug is already approved for heart failure; its superiority over valsartan alone for hypertension is not guaranteed. Side effects like low blood pressure or dizziness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

Contacts and locations

Locations

Wonju Severance Christian Hospital
RECRUITING

Wŏnju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.